NCT00358371View on ClinicalTrials.gov

Bioavailability Of Flucloxacillin Capsules (250 mg and 500 mg)

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

January 6, 2005

Primary Completion Date

February 8, 2005

Study Completion Date

February 8, 2005

Conditions
Infections, Bacterial
Interventions
DRUG

flucloxacillin 250 mg

Subjects will be randomized to receive single oral dose of 250 mg flucloxacillin capsule and 250 mg Intravenous dose

DRUG

flucloxacillin 500 mg

Subjects will be randomized to receive single oral dose of 500 mg flucloxacillin capsule and 500 mg Intravenous dose

Trial Locations (1)

17487

GSK Investigational Site, Greifswald

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT00358371 - Bioavailability Of Flucloxacillin Capsules (250 mg and 500 mg) | Biotech Hunter | Biotech Hunter